CRBU
Caribou Biosciences, Inc.
There isn't enough reported data to score CRBU yet.
CRBU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CRBU's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
CRBU PE Valuation
CRBU has no meaningful PE right now: it lost money over the past year.
CRBU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CRBU's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
CRBU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.03 | +$0.67 |
| Q2 2026 | -$1.08 | +$0.70 |
| Q1 2026 | -$1.42 | +$0.20 |
| Q4 2025 | -$1.59 | +$0.06 |
| Q3 2025 | -$1.70 | -$0.12 |
| Q2 2025 | -$1.78 | -$0.46 |
| Q1 2025 | -$1.62 | -$0.24 |
| Q4 2024 | -$1.65 | -$0.27 |
CRBU is still losing money, but far less than before: $1.03 per share over the past year, against $2.86 at its worst in late 2021.
CRBU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -27% |
| Q2 2026 | $1.5M | -44% |
| Q1 2026 | $2.4M | +1.9% |
| Q4 2025 | $3.9M | +90% |
| Q3 2025 | $2.2M | +8.6% |
| Q2 2025 | $2.7M | -23% |
| Q1 2025 | $2.4M | -3.1% |
| Q4 2024 | $2.1M | -42% |
CRBU's revenue fell from its 2023 peak and has held roughly level since: $2M last quarter, down 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1720% | -383 points |
| Q2 2026 | -1690% | +94 points |
| Q1 2026 | -1096% | +727 points |
| Q4 2025 | -722% | +1150 points |
| Q3 2025 | -1338% | +552 points |
| Q2 2025 | -1784% | -528 points |
| Q1 2025 | -1824% | +70 points |
| Q4 2024 | -1872% | -819 points |
CRBU's operating margin was −1720% last quarter, down 383 points from the same quarter a year ago.
CRBU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.5M | +$2.8M |
| Q2 2026 | -$22.8M | +$5.9M |
| Q1 2026 | -$27.1M | +$10.7M |
| Q4 2025 | -$20.6M | +$15.4M |
| Q3 2025 | -$25.3M | +$8M |
| Q2 2025 | -$28.7M | +$6.4M |
| Q1 2025 | -$37.8M | +$884K |
| Q4 2024 | -$36M | -$12.3M |
CRBU has burned cash in almost every quarter: −$93M over the past year, against −$128M the year before.
CRBU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.5% | +6.6M shares |
| 1 year | +15% | +14.2M shares |
| 3 years | +28% | +23.8M shares |
| 5 years | +134% | +61.6M shares |
| Available history | +289% | +79.9M shares |
CRBU has 108M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRBU Net Leverage
CRBU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CRBU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 1.8 | Oversold |
CRBU's weekly RSI is 26 (oversold) and its Stochastic is 2 (oversold).
CRBU PE vs Healthcare Sector
CRBU has no meaningful PE right now: it lost money over the past year.
CRBU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.65 | 42% below |
| 20 week MA | $1.21 | 69% below |
| 50 week MA | $1.57 | 76% below |
| 100 week MA | $1.56 | 76% below |
| 200 week MA | $2.98 | 87% below |
CRBU is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
CRBU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.3 | $16.2 | -0.9% |
| 2022 | $16.2 | $6.16 | -62% |
| 2023 | $6.16 | $5.73 | -7% |
| 2024 | $5.73 | $1.67 | -71% |
| 2025 | $1.67 | $1.70 | +1.8% |
| 2026 YTD | $1.70 | $0.38 | -78% |
CRBU has finished lower in four of the last five years. It's down 78% so far in 2026.